Literature DB >> 15837235

Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults.

Janet E McElhaney1, Jonathan W Hooton, Nicola Hooton, R Chris Bleackley.   

Abstract

This study compared the immune response to the standard single-dose (SD) of influenza vaccine to a booster dose (BD) re-vaccination given 16 weeks after the initial dose. While seroprotection rates following vaccination were similar, T-cell responses were more optimally stimulated in the SD versus the BD group. SD lead to a greater than 10-fold decline in ex vivo interleukin-10 (IL-10) levels (P < .0001) and a corresponding significant increase in the interferon-gamma (IFN-gamma) to IL-10 ratio. Although BD had no further effect on IL-10 production, the IFN-gamma:IL-10 ratio declined in the BD group (P < .001, A/H3N2 and B strains). In the SD group only, IFN-gamma:IL-10 ratios significantly correlated with serum antibody titers (R = .37 - .50, P < or = .01) and ex vivo granzyme B (Grz B) levels (R = .50-.65, P < or = .001). Following vaccination, granzyme B levels were significantly higher in the SD compared to the BD group (P < or= .0002). These results suggest that SD influenza vaccine produces Th1 and CTL responses while BD may produce a Th2 response that poorly stimulates the CTL response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837235     DOI: 10.1016/j.vaccine.2005.01.080

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.

Authors:  Meagan Bolles; Damon Deming; Kristin Long; Sudhakar Agnihothram; Alan Whitmore; Martin Ferris; William Funkhouser; Lisa Gralinski; Allison Totura; Mark Heise; Ralph S Baric
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host.

Authors:  Hugues de Lavallade; Paula Garland; Takuya Sekine; Katja Hoschler; David Marin; Kate Stringaris; Eva Loucaides; Katherine Howe; Richard Szydlo; Ed Kanfer; Donald Macdonald; Peter Kelleher; Nichola Cooper; Ahmad Khoder; Ian H Gabriel; Dragana Milojkovic; Jiri Pavlu; John M Goldman; Jane F Apperley; Katayoun Rezvani
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

3.  Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine.

Authors:  Mary Dawn T Co; Laura Orphin; John Cruz; Pamela Pazoles; Alan L Rothman; Francis A Ennis; Masanori Terajima
Journal:  Vaccine       Date:  2008-02-26       Impact factor: 3.641

4.  The regulatory T cells in anti-influenza antibody response post influenza vaccination.

Authors:  Shih-Min Wang; Ming-Hsun Tsai; Huan-Yao Lei; Jen-Ren Wang; Ching-Chuan Liu
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

Review 5.  Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.

Authors:  Barbara Camilloni; Michela Basileo; Stefano Valente; Emilia Nunzi; Anna Maria Iorio
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study.

Authors:  Amy Van Ermen; Matthew P Hermanson; John M Moran; Nancy K Sweitzer; Maryl R Johnson; Orly Vardeny
Journal:  Eur J Heart Fail       Date:  2013-01-04       Impact factor: 15.534

7.  Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults.

Authors:  Xu Yao; Robert G Hamilton; Nan-ping Weng; Qian-Li Xue; Jay H Bream; Huifen Li; Jing Tian; Shu-Hui Yeh; Barbara Resnick; Xiyan Xu; Jeremy Walston; Linda P Fried; Sean X Leng
Journal:  Vaccine       Date:  2011-05-10       Impact factor: 3.641

8.  Correlation between rubella antibody levels and cytokine measures of cell-mediated immunity.

Authors:  Pritish K Tosh; Richard B Kennedy; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

9.  B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant.

Authors:  Jane Baer; Felix Santiago; Hongmei Yang; Hulin Wu; Jeanne Holden-Wiltse; John Treanor; David J Topham
Journal:  Vaccine       Date:  2009-11-21       Impact factor: 3.641

Review 10.  Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients.

Authors:  Arnt-Ove Hovden; Rebecca Jane Cox; Lars Reinhardt Haaheim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.